|
業務類別
|
Biotechnology |
|
業務概覽
|
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept. |
| 公司地址
| 355 Alhambra Circle, Suite 801, Coral Gables, FL, USA, 33134 |
| 電話號碼
| +1 305 420-3200 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.catalystpharma.com |
| 員工數量
| 182 |
| Dr. Steven R. Miller,PhD |
Executive Vice President, Chief Operating Officer and Chief Scientific Officer |
美元 560.00K |
11/04/2025 |
| Dr. Gary Ingenito,M.D.,PhD |
Chief Medical and Regulatory Officer |
-- |
11/04/2025 |
| Mr. Jeffrey Del Carmen |
Executive Vice President and Chief Commercial Officer |
美元 525.00K |
11/04/2025 |
| Mr. Richard J. Daly |
Director, President and Chief Executive Officer |
美元 750.00K |
25/02/2026 |
| Mr. Michael W. Kalb, C.P.A. |
Executive Vice President,Treasurer, Chief Financial Officer and Principal Accounting Officer |
美元 525.00K |
25/02/2026 |
| Dr. Preethi Sundaram, PhD |
Chief Strategy Officer |
美元 485.00K |
11/04/2025 |
| Mr. Gregg Russo |
Chief Human Resources Officer |
-- |
11/04/2025 |
| Mr. Brian Elsbernd, J.D. |
Chief Compliance Officer and Chief Legal Officer |
-- |
11/04/2025 |
|
|
| Mr. Patrick J. McEnany |
Non-Executive Chairman of the Board |
25/02/2026 |
| Ms. Molly Harper |
Lead Independent Director |
25/02/2026 |
| Mr. Daniel Curran, M.D. |
Director |
25/02/2026 |
| Dr. David S. Tierney,M.D. |
Independent Director |
25/02/2026 |
| Mr. Donald A. Denkhaus |
Independent Director |
25/02/2026 |
| Mr. Richard J. Daly |
Director, President and Chief Executive Officer |
25/02/2026 |
| Ms. Tamar Thompson |
Independent Director |
25/02/2026 |
|
|
|
|
